

START GETTING BETTER RESULTS, FASTER

Individualizing your cancer treatment to improve outcomes through genomics.

What is PCDx?



FAST

Comprehensive genomic results and targeted treatment report within 5 business days



EFFICIENT

We provide full results on even the smallest of solid tumor specimens



INEXPENSIVE

PCDx is covered by most insurance plans and Medicare and has a generous financial assistance policy



COMPREHENSIVE

PCDx uncovers the biomarkers associated almost twice as many FDA approved drugs and combinations as typical genomic approaches and also lists all associated biomarker driven clinical trials



EFFECTIVE

Numerous published prospective clinical studies show that treatment informed PCDx can significantly improve progression free survival

SOME QUESTIONS TO ASK YOUR PHYSICIAN

- 1 What targeted therapies or immunotherapies might be available for my cancer?
- 2 How might you use the results of a comprehensive genomic test like PCDx for my treatment?
- 3 What are my options if I don't have genomic profiling performed?
- 4 Do I have enough tissue sample available?
- 5 Can you complete the requisition and request for the pathologist to send my specimen to Paradigm?

ORDERING INFORMATION

Please print our requisition and bring to your oncologist to order PCDx to help better illuminate all of the treatment pathways that may improve progression free survival.

Our Customer Service will then reach out to pathology to have your specimen sent to us for comprehensive PCDx analysis.

WE ARE HERE TO HELP

Please feel free to call our Customer Service Representatives at **844.232.4719** or send an email to customerservice@paradigmdx.com with any questions you may have, including ordering, specimen collection, physician feedback, insurance, or the results.

ABOUT PARADIGM

Paradigm was established to bring cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients. Through Next Generation Sequencing (NGS) and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient's cancer, as well as potential therapies based on the specific characterization of the patient's tumor; thus, personalizing each patient's course of treatment. See www.paradigmdx.com for additional information.